{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:32:58Z","timestamp":1776180778426,"version":"3.50.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40259-024-00687-w","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T03:14:42Z","timestamp":1732763682000},"page":"53-74","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa"],"prefix":"10.1007","volume":"39","author":[{"given":"Gon\u00e7alo","family":"Pinto Salgueiro","sequence":"first","affiliation":[]},{"given":"Orhan","family":"Yilmaz","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Nogueira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"issue":"6","key":"687_CR1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/ddg.15412","volume":"22","author":"CC Zouboulis","year":"2024","unstructured":"Zouboulis CC, Bechara FG, Fritz K, Goebeler M, Hetzer FH, Just E, Kirsten N, Kokolakis G, Kurzen H, Nikolakis G, Pinter A, Podda M, Rosinski K, Schneider-Burrus S, Taube KM, Volz T, Winkler T, Kristandt A, Presser D, Zouboulis VA. S2k guideline for the treatment of hidradenitis suppurativa \/ acne inversa - Short version. J Dtsch Dermatol Ges. 2024;22(6):868\u201389. https:\/\/doi.org\/10.1111\/ddg.15412.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"687_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GB. Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231(2):184\u201390. https:\/\/doi.org\/10.1159\/000431175.","journal-title":"Dermatology"},{"issue":"5","key":"687_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045\u201358. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.090.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"687_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","volume":"153","author":"A Garg","year":"2017","unstructured":"Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760\u20134. https:\/\/doi.org\/10.1001\/jamadermatol.2017.0201.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"687_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.20344\/amp.18916","volume":"36","author":"J Cabete","year":"2023","unstructured":"Cabete J, Apar\u00edcio MI. Recommendations on the approach to the patient with hidradenitis suppurativa. Acta Med Port. 2023;36(2):133\u20139. https:\/\/doi.org\/10.20344\/amp.18916.","journal-title":"Acta Med Port"},{"issue":"1","key":"687_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak \u0141, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18. https:\/\/doi.org\/10.1038\/s41572-020-0149-1.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"687_CR7","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1111\/bjd.16768","volume":"183","author":"KR van Straalen","year":"2020","unstructured":"van Straalen KR, Schneider-Burrus S, Prens EP. Current and future treatment of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):e178\u201387. https:\/\/doi.org\/10.1111\/bjd.16768.","journal-title":"Br J Dermatol"},{"issue":"5","key":"687_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","volume":"20","author":"CA Maronese","year":"2024","unstructured":"Maronese CA, Moltrasio C, Genovese G, Marzano AV. Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol. 2024;20(5):525\u201345. https:\/\/doi.org\/10.1080\/1744666X.2023.2298356.","journal-title":"Expert Rev Clin Immunol"},{"key":"687_CR9","unstructured":"Buchanan L. European Union Approves Bimekizumab to Treat HS. Dermatology Times. Available at https:\/\/www.dermatologytimes.com\/view\/european-union-approves-bimekizumab-to-treat-hs. Accessed 14 July 2024."},{"issue":"1","key":"687_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jaad.2024.03.028","volume":"91","author":"JP Pham","year":"2024","unstructured":"Pham JP, Rosen\u00f8 NAL, Roccuzzo G, Saal RC, Egeberg A, Ring HC, Frew JW. Drug survival of biologics in hidradenitis suppurativa: a systematic review and meta-analysis. J Am Acad Dermatol. 2024;91(1):170\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.028.","journal-title":"J Am Acad Dermatol"},{"key":"687_CR11","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.3389\/fimmu.2018.02965","volume":"9","author":"ARJV Vossen","year":"2018","unstructured":"Vossen ARJV, van der Zee HH, Prens EP. Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol. 2018;9:2965. https:\/\/doi.org\/10.3389\/fimmu.2018.02965.","journal-title":"Front Immunol"},{"key":"687_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-80027-7_23","volume-title":"New and emerging entities in dermatology and dermatopathology","author":"G Genovese","year":"2021","unstructured":"Genovese G, Moltrasi C, Marzano AV. PAPA, PASH, PAPASH, PsAPASH, and PASS: autoinflammatory syndromes of hidradenitis suppurativa. In: Rongioletti F, Smoller BR, editors. New and emerging entities in dermatology and dermatopathology. Cham: Springer; 2021. https:\/\/doi.org\/10.1007\/978-3-030-80027-7_23."},{"issue":"12","key":"687_CR13","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/exd.14214","volume":"29","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis CC, Benhadou F, Byrd AS, et al. What causes hidradenitis suppurativa\u202f?-15 years after. Exp Dermatol. 2020;29(12):1154\u201370. https:\/\/doi.org\/10.1111\/exd.14214.","journal-title":"Exp Dermatol"},{"issue":"5","key":"687_CR14","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","volume":"83","author":"JW Frew","year":"2020","unstructured":"Frew JW, Navrazhina K, Grand D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83(5):1341\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2020.05.007.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"687_CR15","doi-asserted-by":"publisher","first-page":"7546","DOI":"10.4081\/dr.2018.7546","volume":"10","author":"YT Melibary","year":"2018","unstructured":"Melibary YT. Hidradenitis suppurativa in a patient with hyperandrogenism, insulin-resistance and acanthosis nigricans (HAIR-AN syndrome). Dermatol Rep. 2018;10(1):7546. https:\/\/doi.org\/10.4081\/dr.2018.7546.","journal-title":"Dermatol Rep"},{"issue":"6","key":"687_CR16","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/bjd.17908","volume":"180","author":"E Contassot","year":"2019","unstructured":"Contassot E, French LE. A new link between autoinflammation and hidradenitis suppurativa? Br J Dermatol. 2019;180(6):1294\u20135. https:\/\/doi.org\/10.1111\/bjd.17908.","journal-title":"Br J Dermatol"},{"issue":"13","key":"687_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.861241","volume":"23","author":"NP Pace","year":"2022","unstructured":"Pace NP, Mintoff D, Borg I. The genomic architecture of hidradenitis suppurativa-a systematic review. Front Genet. 2022;23(13): 861241. https:\/\/doi.org\/10.3389\/fgene.2022.861241.","journal-title":"Front Genet"},{"issue":"9","key":"687_CR18","doi-asserted-by":"publisher","first-page":"8428","DOI":"10.3390\/ijms24098428","volume":"24","author":"E Molinelli","year":"2023","unstructured":"Molinelli E, Gioacchini H, Sapigni C, et al. New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa. Int J Mol Sci. 2023;24(9):8428. https:\/\/doi.org\/10.3390\/ijms24098428.","journal-title":"Int J Mol Sci"},{"key":"687_CR19","doi-asserted-by":"publisher","first-page":"1759720X1989548","DOI":"10.1177\/1759720X19895488","volume":"11","author":"CA Constantinou","year":"2019","unstructured":"Constantinou CA, Fragoulis GE, Nikiphorou E. Hidradenitis suppurativa: infection, autoimmunity, or both? Ther Adv Musculoskelet Dis. 2019;11:1759720X19895488. https:\/\/doi.org\/10.1177\/1759720X19895488.","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"1","key":"687_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/jdv.16677","volume":"35","author":"TV Nguyen","year":"2021","unstructured":"Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50\u201361. https:\/\/doi.org\/10.1111\/jdv.16677.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"687_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2133.2010.10034.x","volume":"164","author":"M von Laffert","year":"2011","unstructured":"von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa\/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. 2011;164(2):367\u201371. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10034.x.","journal-title":"Br J Dermatol"},{"issue":"7","key":"687_CR22","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jid.2020.01.023","volume":"140","author":"ARJV Vossen","year":"2020","unstructured":"Vossen ARJV, van Straalen KR, Florencia EF, Prens EP. Lesional inflammatory profile in hidradenitis suppurativa is not solely driven by IL-1. J Invest Dermatol. 2020;140(7):1463-1466.e2. https:\/\/doi.org\/10.1016\/j.jid.2020.01.023.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"687_CR23","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jid.2019.08.445","volume":"140","author":"HB Naik","year":"2020","unstructured":"Naik HB, Jo JH, Paul M, Kong HH. Skin microbiota perturbations are distinct and disease severity-dependent in hidradenitis suppurativa. J Invest Dermatol. 2020;140(4):922-925.e3. https:\/\/doi.org\/10.1016\/j.jid.2019.08.445.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"687_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/cid\/cix285","volume":"65","author":"H Guet-Revillet","year":"2017","unstructured":"Guet-Revillet H, Jais JP, Ungeheuer MN, et al. The microbiological landscape of anaerobic infections in hidradenitis suppurativa: a prospective metagenomic study. Clin Infect Dis. 2017;65(2):282\u201391. https:\/\/doi.org\/10.1093\/cid\/cix285.","journal-title":"Clin Infect Dis"},{"issue":"19","key":"687_CR25","doi-asserted-by":"publisher","first-page":"11280","DOI":"10.3390\/ijms231911280","volume":"23","author":"Z \u015awierczewska","year":"2022","unstructured":"\u015awierczewska Z, Lewandowski M, Surowiecka A, Bara\u0144ska-Rybak W. Microbiome in hidradenitis suppurativa-what we know and where we are heading. Int J Mol Sci. 2022;23(19):11280. https:\/\/doi.org\/10.3390\/ijms231911280.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"687_CR26","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.jid.2016.04.036","volume":"136","author":"C Hotz","year":"2016","unstructured":"Hotz C, Boniotto M, Guguin A, et al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J Invest Dermatol. 2016;136(9):1768\u201380. https:\/\/doi.org\/10.1016\/j.jid.2016.04.036.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"687_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/exd.13482","volume":"27","author":"R Thomi","year":"2018","unstructured":"Thomi R, Schlapbach C, Yawalkar N, Simon D, Yerly D, Hunger RE. Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1\/Th17 immune response. Exp Dermatol. 2018;27(2):172\u20137. https:\/\/doi.org\/10.1111\/exd.13482.","journal-title":"Exp Dermatol"},{"issue":"3","key":"687_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/exd.13885","volume":"28","author":"R Kjaersgaard Andersen","year":"2019","unstructured":"Kjaersgaard Andersen R, Ring HC, Kallenbach K, Eriksen JO, Jemec GBE. Bacterial biofilm is associated with higher levels of regulatory T cells in unaffected hidradenitis suppurativa skin. Exp Dermatol. 2019;28(3):312\u20136. https:\/\/doi.org\/10.1111\/exd.13885.","journal-title":"Exp Dermatol"},{"issue":"2","key":"687_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cei.13449","volume":"201","author":"JM Fletcher","year":"2020","unstructured":"Fletcher JM, Moran B, Petrasca A, Smith CM. IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clin Exp Immunol. 2020;201(2):121\u201334. https:\/\/doi.org\/10.1111\/cei.13449.","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"687_CR30","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","volume":"192","author":"S Cheuk","year":"2014","unstructured":"Cheuk S, Wik\u00e9n M, Blomqvist L, et al. Epidermal Th22 and Tc17 cells form a localised disease memory in clinically healed psoriasis. J Immunol. 2014;192(7):3111\u201320. https:\/\/doi.org\/10.4049\/jimmunol.1302313.","journal-title":"J Immunol"},{"issue":"1","key":"687_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41467-018-07911-6.PMID:30602780;PMCID:PMC6315029","volume":"10","author":"K Venken","year":"2019","unstructured":"Venken K, Jacques P, Mortier C, et al. ROR\u03b3t inhibition selectively targets IL-17 producing iNKT and \u03b3\u03b4-T cells enriched in Spondyloarthritis patients. Nat Commun. 2019;10(1):9. https:\/\/doi.org\/10.1038\/s41467-018-07911-6.PMID:30602780;PMCID:PMC6315029.","journal-title":"Nat Commun"},{"issue":"9","key":"687_CR32","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1038\/jid.2014.146","volume":"134","author":"MBM Teunissen","year":"2014","unstructured":"Teunissen MBM, Munneke JM, Bernink JH, et al. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients. J Invest Dermatol. 2014;134(9):2351\u201360. https:\/\/doi.org\/10.1038\/jid.2014.146.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"687_CR33","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.4049\/jimmunol.1103014","volume":"189","author":"JM Reynolds","year":"2012","unstructured":"Reynolds JM, Martinez GJ, Nallaparaju KC, Chang SH, Wang YH, Dong C. Cutting edge: regulation of intestinal inflammation and barrier function by IL-17C. J Immunol. 2012;189(9):4226\u201330. https:\/\/doi.org\/10.4049\/jimmunol.1103014.","journal-title":"J Immunol"},{"key":"687_CR34","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","volume":"9","author":"NC Brembilla","year":"2018","unstructured":"Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682. https:\/\/doi.org\/10.3389\/fimmu.2018.01682.","journal-title":"Front Immunol"},{"issue":"36","key":"687_CR35","doi-asserted-by":"publisher","first-page":"aau9657","DOI":"10.1126\/sciimmunol.aau9657","volume":"4","author":"Y Su","year":"2019","unstructured":"Su Y, Huang J, Zhao X, et al. Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation. Sci Immunol. 2019;4(36):aau9657. https:\/\/doi.org\/10.1126\/sciimmunol.aau9657.","journal-title":"Sci Immunol."},{"issue":"11","key":"687_CR36","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1006\/cyto.1997.0240","volume":"9","author":"Z Yao","year":"1997","unstructured":"Yao Z, Spriggs MK, Derry JM, et al. Molecular characterisation of the human interleukin (IL)-17 receptor. Cytokine. 1997;9(11):794\u2013800. https:\/\/doi.org\/10.1006\/cyto.1997.0240.","journal-title":"Cytokine"},{"issue":"4","key":"687_CR37","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","volume":"50","author":"MJ McGeachy","year":"2019","unstructured":"McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892\u2013906. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.021.","journal-title":"Immunity"},{"issue":"4","key":"687_CR38","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","volume":"65","author":"C Schlapbach","year":"2011","unstructured":"Schlapbach C, H\u00e4nni T, Yawalkar N, Hunger RE. Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2010.07.010.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"687_CR39","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/bjd.14075","volume":"173","author":"G Kelly","year":"2015","unstructured":"Kelly G, Hughes R, McGarry T, et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol. 2015;173(6):1431\u20139. https:\/\/doi.org\/10.1111\/bjd.14075.","journal-title":"Br J Dermatol"},{"issue":"11","key":"687_CR40","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","volume":"137","author":"B Moran","year":"2017","unstructured":"Moran B, Sweeney CM, Hughes R, et al. Hidradenitis suppurativa is characterised by dysregulation of the Th17: Treg cell axis, which is corrected by anti-TNF therapy. J Invest Dermatol. 2017;137(11):2389\u201395. https:\/\/doi.org\/10.1016\/j.jid.2017.05.033.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"687_CR41","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/14740338.2021.1924147","volume":"20","author":"ZE Holcomb","year":"2021","unstructured":"Holcomb ZE, Porter ML, Kimball AB. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opin Drug Saf. 2021;20(10):1147\u201361. https:\/\/doi.org\/10.1080\/14740338.2021.1924147.","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"687_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105238","volume":"9","author":"HL Kelh\u00e4l\u00e4","year":"2014","unstructured":"Kelh\u00e4l\u00e4 HL, Palatsi R, Fyhrquist N, et al. IL-17\/Th17 pathway is activated in acne lesions. PLoS ONE. 2014;9(8): e105238. https:\/\/doi.org\/10.1371\/journal.pone.0105238.","journal-title":"PLoS ONE"},{"issue":"6","key":"687_CR43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2340\/00015555-0749","volume":"89","author":"L Matusiak","year":"2009","unstructured":"Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89(6):601\u20133. https:\/\/doi.org\/10.2340\/00015555-0749.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"687_CR44","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","volume":"76","author":"\u0141 Matusiak","year":"2017","unstructured":"Matusiak \u0141, Szcz\u0119ch J, Bieniek A, Nowicka-Suszko D, Szepietowski JC. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76(4):670\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.042.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"687_CR45","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bjd.15769","volume":"179","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2018;179(1):182\u20135. https:\/\/doi.org\/10.1111\/bjd.15769.","journal-title":"Br J Dermatol"},{"issue":"1","key":"687_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2340\/00015555-2794","volume":"98","author":"A Schuch","year":"2018","unstructured":"Schuch A, Fischer T, Boehner A, Biedermann T, Volz T. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab. Acta Derm Venereol. 2018;98(1):151\u20132. https:\/\/doi.org\/10.2340\/00015555-2794.","journal-title":"Acta Derm Venereol"},{"key":"687_CR47","doi-asserted-by":"publisher","first-page":"8685136","DOI":"10.1155\/2018\/8685136","volume":"2018","author":"AR J\u00f8rgensen","year":"2018","unstructured":"J\u00f8rgensen AR, Yao Y, Thomsen SF. Therapeutic Response to Secukinumab in a 36-Year-Old Woman with Hidradenitis Suppurativa. Case Rep Dermatol Med. 2018;2018:8685136. https:\/\/doi.org\/10.1155\/2018\/8685136.","journal-title":"Case Rep Dermatol Med."},{"issue":"6","key":"687_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13845","volume":"33","author":"A G\u0142owaczewska","year":"2020","unstructured":"G\u0142owaczewska A, Szepietowski JC, Matusiak \u0141. Severe hidradenitis suppurativa successfully treated with secukinumab. Dermatol Ther. 2020;33(6): e13845. https:\/\/doi.org\/10.1111\/dth.13845.","journal-title":"Dermatol Ther"},{"issue":"8","key":"687_CR49","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.ad.2019.07.007","volume":"111","author":"I Villegas-Romero","year":"2020","unstructured":"Villegas-Romero I, Collantes-Rodr\u00edguez C, Valenzuela-Ubi\u00f1a S, Jim\u00e9nez-Gallo D. Moderate to severe hidradenitis suppurativa successfully treated with secukinumab. Moderate to severe hidradenitis suppurativa successfully treated with secukinumab. Actas Dermosifiliogr (Engl Ed). 2020;111(8):696\u20138. https:\/\/doi.org\/10.1016\/j.ad.2019.07.007.","journal-title":"Actas Dermosifiliogr (Engl Ed)."},{"issue":"11","key":"687_CR50","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/ijd.15209","volume":"59","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi A, Garcovich S, Malvaso D, Giovanardi G, Peris K. COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus. Int J Dermatol. 2020;59(11):1423\u20134. https:\/\/doi.org\/10.1111\/ijd.15209.","journal-title":"Int J Dermatol"},{"issue":"3","key":"687_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/bjd.17822","volume":"181","author":"L Prussick","year":"2019","unstructured":"Prussick L, Rothstein B, Joshipura D, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609\u201311. https:\/\/doi.org\/10.1111\/bjd.17822.","journal-title":"Br J Dermatol"},{"key":"687_CR52","unstructured":"National Library of Medicine. Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03099980. Accessed 26 June 2024."},{"issue":"6","key":"687_CR53","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","volume":"82","author":"RG Casseres","year":"2020","unstructured":"Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial. J Am Acad Dermatol. 2020;82(6):1524\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2020.02.005.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"687_CR54","doi-asserted-by":"publisher","first-page":"e750","DOI":"10.1111\/jdv.16605","volume":"34","author":"Z Reguia\u00ef","year":"2020","unstructured":"Reguia\u00ef Z, Fougerousse AC, Maccari F, B\u00e9cherel PA. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). J Eur Acad Dermatol Venereol. 2020;34(11):e750\u20131. https:\/\/doi.org\/10.1111\/jdv.16605.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"687_CR55","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1111\/jdv.17178","volume":"35","author":"S Ribero","year":"2021","unstructured":"Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. 2021;35(7):e441\u20132. https:\/\/doi.org\/10.1111\/jdv.17178.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"687_CR56","unstructured":"National Library of Medicine. This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). (SUNSHINE). Available at: https:\/\/clinicaltrials.gov\/study\/NCT03713619. Accessed 28 May 2024."},{"key":"687_CR57","unstructured":"National Library of Medicine. Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) (SUNRISE). Available at: https:\/\/clinicaltrials.gov\/study\/NCT03713632. Accessed 28 May 2024."},{"issue":"10378","key":"687_CR58","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials [published correction appears in Lancet. 2024 Feb 17;403(10427):618]. Lancet. 2023;401(10378):747\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(23)00022-3.","journal-title":"Lancet"},{"key":"687_CR59","doi-asserted-by":"publisher","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","volume":"102","author":"AB Gottlieb","year":"2022","unstructured":"Gottlieb AB, Deodhar A, Mcinnes IB, et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data. Acta Derm Venereol. 2022;102:adv00698. https:\/\/doi.org\/10.2340\/actadv.v102.563.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"687_CR60","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/bjd.18093","volume":"182","author":"HH Lee","year":"2020","unstructured":"Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults. Br J Dermatol. 2020;182(2):327\u201334. https:\/\/doi.org\/10.1111\/bjd.18093.","journal-title":"Br J Dermatol"},{"issue":"4","key":"687_CR61","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40257-022-00686-z","volume":"23","author":"M Yamanaka-Takaichi","year":"2022","unstructured":"Yamanaka-Takaichi M, Ghanian S, Katzka DA, Torgerson RR, Alavi A. Candida infection associated with anti-IL-17 medication: a systematic analysis and review of the literature. Am J Clin Dermatol. 2022;23(4):469\u201380. https:\/\/doi.org\/10.1007\/s40257-022-00686-z.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"687_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15140","volume":"33","author":"G Roccuzzo","year":"2024","unstructured":"Roccuzzo G, Repetto F, Giordano S, Sarda C, Comes A, Dapavo P, Quaglino P, Ribero S. Anti-IL17 Secukinumab in hidradenitis suppurativa: A long-term drug survival analysis. Exp Dermatol. 2024;33(7): e15140. https:\/\/doi.org\/10.1111\/exd.15140.","journal-title":"Exp Dermatol"},{"key":"687_CR63","unstructured":"National Library of Medicine. Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04179175. Accessed 28 May 2024."},{"key":"687_CR64","unstructured":"National Library of Medicine. Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa. (ANIMA). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05921994. Accessed 28 May 2024."},{"key":"687_CR65","unstructured":"National Library of Medicine. Patient\u2019s Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation (SPECTRA). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06444087. Accessed 26 June 2024."},{"key":"687_CR66","unstructured":"National Library of Medicine. Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05583604. Accessed 26 June 2024."},{"issue":"10370","key":"687_CR67","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","volume":"401","author":"JF Merola","year":"2023","unstructured":"Merola JF, Landew\u00e9 R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(22)02303-0.","journal-title":"Lancet"},{"issue":"11","key":"687_CR68","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","volume":"157","author":"S Glatt","year":"2021","unstructured":"Glatt S, Jemec GBE, Forman S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind placebo-controlled randomized clinical trial [published correction appears in JAMA Dermatol. 2021 Nov 1;157(11):1384]. JAMA Dermatol. 2021;157(11):1279\u201388. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2905.","journal-title":"JAMA Dermatol"},{"key":"687_CR69","unstructured":"National Library of Medicine. A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03248531. Accessed 26 June 2024."},{"key":"687_CR70","unstructured":"National Library of Medicine. A Study to Evaluate the Efficacy and Safety of Bimekizumabin Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD I). Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT04242446. Accessed 28 May 2024."},{"key":"687_CR71","unstructured":"National Library of Medicine. A Study to Evaluate the Efficacy and Safety of Bimekizumabin Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD II). 2020 Clinical Trial Registration NCT04242498, ClinicalTrials.gov. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT04242498. Accessed 28 May 2024."},{"key":"687_CR72","unstructured":"National Library of Medicine. A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD EXT). Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT04901195. Accessed 28 May 2024."},{"key":"687_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00101-6","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024. https:\/\/doi.org\/10.1016\/S0140-6736(24)00101-6.","journal-title":"Lancet"},{"issue":"2","key":"687_CR74","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. N Engl J Med. 2021;385(2):142\u201352. https:\/\/doi.org\/10.1056\/NEJMoa2102383.","journal-title":"N Engl J Med"},{"key":"687_CR75","unstructured":"Golbari NM, Basehore BM, Zito PM. Brodalumab. In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 8, 2023."},{"issue":"1","key":"687_CR76","doi-asserted-by":"publisher","first-page":"2270091","DOI":"10.1080\/09546634.2023.2270091","volume":"34","author":"E Vagnozzi","year":"2023","unstructured":"Vagnozzi E, Bruni M, Esposito M, Fargnoli MC. Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review. J Dermatolog Treat. 2023;34(1):2270091. https:\/\/doi.org\/10.1080\/09546634.2023.2270091.","journal-title":"J Dermatolog Treat"},{"key":"687_CR77","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.12688\/f1000research.21216.2","volume":"8","author":"E Tampouratzi","year":"2019","unstructured":"Tampouratzi E, Kanni T, Katsantonis J, Douvali T. Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches. F1000Res. 2019;8:2002. https:\/\/doi.org\/10.12688\/f1000research.21216.2.","journal-title":"F1000Res"},{"issue":"6","key":"687_CR78","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/1346-8138.15807","volume":"48","author":"Y Yoshida","year":"2021","unstructured":"Yoshida Y, Oyama N, Iino S, Shimizu C, Hasegawa M. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: a possible involvement of Th17 across the spectrum of both diseases. J Dermatol. 2021;48(6):916\u201320. https:\/\/doi.org\/10.1111\/1346-8138.15807.","journal-title":"J Dermatol"},{"issue":"6","key":"687_CR79","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/ijd.14792","volume":"59","author":"M Arenbergerova","year":"2020","unstructured":"Arenbergerova M, Arenberger P, Marques E, Gkalpakiotis S. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure [published correction appears in Int J Dermatol. 2023 Jun;62(6):843]. Int J Dermatol. 2020;59(6):733\u20135. https:\/\/doi.org\/10.1111\/ijd.14792.","journal-title":"Int J Dermatol"},{"issue":"3","key":"687_CR80","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/ajd.14267","volume":"65","author":"GF Osorio-G\u00f3mez","year":"2024","unstructured":"Osorio-G\u00f3mez GF, Ortiz-\u00c1lvarez J, Diaz-Ceca D, Guijarro-S\u00e1nchez C, Conejo-Mir S\u00e1nchez J, Fern\u00e1ndez Crehuet P. Brodalumab for moderate\u2013severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice. Australas J Dermatol. 2024;65(3):254\u20139. https:\/\/doi.org\/10.1111\/ajd.14267.","journal-title":"Australas J Dermatol"},{"issue":"7","key":"687_CR81","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ced\/llad130","volume":"48","author":"N Kearney","year":"2023","unstructured":"Kearney N, Hughes R, Kirby B. Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic. Clin Exp Dermatol. 2023;48(7):790\u20132. https:\/\/doi.org\/10.1093\/ced\/llad130.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"687_CR82","doi-asserted-by":"publisher","first-page":"e884","DOI":"10.1111\/jdv.17536","volume":"35","author":"JW Frew","year":"2021","unstructured":"Frew JW, Grand D, Navrazhina K, Garcet S, Krueger JG. Assessing the responsiveness of sonographic biomarkers to Brodalumab therapy in Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol. 2021;35(12):e884\u20137. https:\/\/doi.org\/10.1111\/jdv.17536.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"687_CR83","unstructured":"National Library of Medicine. Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03960268. Accessed 26 June 2024."},{"key":"687_CR84","unstructured":"National Library of Medicine. A Small Pilot Study to Develop Biomarkers of Weekly Brodalumab Administration in Hidradenitis Suppurativa Patients. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04979520. Accessed 28 May 2024."},{"issue":"1","key":"687_CR85","doi-asserted-by":"publisher","first-page":"2209920","DOI":"10.1080\/19420862.2023.2209920","volume":"15","author":"S Klint","year":"2023","unstructured":"Klint S, Feldwisch J, Gudmundsdotter L, et al. Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralising Affibody molecule in patients with plaque psoriasis. MAbs. 2023;15(1):2209920. https:\/\/doi.org\/10.1080\/19420862.2023.2209920.","journal-title":"MAbs"},{"key":"687_CR86","unstructured":"National Library of Medicine. A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT05355805. Accessed 28 May 2024."},{"key":"687_CR87","unstructured":"ACELYRIN, Inc. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa. Available at: https:\/\/www.prnewswire.com\/news-releases\/acelyrin-inc-announces-izokibep-achieves-hiscr100-responses-at-12-weeks-in-moderate-to-severe-hidradenitis-suppurativa-301775533.html. Accessed 28 May 2024."},{"key":"687_CR88","unstructured":"National Library of Medicine. A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT05905783. Accessed 28 May 2024."},{"issue":"10284","key":"687_CR89","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","volume":"397","author":"KA Papp","year":"2021","unstructured":"Papp KA, Weinberg MA, Morris A, Reich K. IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study [published correction appears in Lancet. 2021 Jun 5;397(10290):2150]. Lancet. 2021;397(10284):1564\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(21)00440-2.","journal-title":"Lancet"},{"key":"687_CR90","unstructured":"National Library of Medicine. Phase 2, Randomised, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Moderate to Severe Hidradenitis Suppurativa. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT05322473. Accessed 28 May 2024."},{"key":"687_CR91","unstructured":"MoonLake Immunotherapeutics Achieves Landmark Milestone with Positive Phase 2 Results for Nanobody\u00ae Sonelokimab in Hidradenitis Suppurativa. Available online: https:\/\/ir.moonlaketx.com\/news-releases\/news-release-details\/moonlake-immunotherapeutics-achieves-landmark-milestone-positive. Accessed 28 May 2024."},{"key":"687_CR92","unstructured":"Kimball AB, Kirby B, Bechara FG, et al. Efficacy and safety of the IL-17A- and IL-17F-inhibiting Nanobody\u00ae sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS); week 24 results from the phase 2 MIRA trial. In: Presented at: American Academy of Dermatology Annual Meeting; 8\u201312 March, 2024; San Diego, California. Abstract 56014."},{"key":"687_CR93","unstructured":"National Library of Medicine. A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT06411899. Accessed 28 May 2024."},{"key":"687_CR94","unstructured":"National Library of Medicine. A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT06411379. Accessed 28 May 2024."},{"issue":"10","key":"687_CR95","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1111\/exd.14619","volume":"31","author":"AB Kimball","year":"2022","unstructured":"Kimball AB, Loesche C, Prens EP, et al. IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study. Exp Dermatol. 2022;31(10):1522\u201332. https:\/\/doi.org\/10.1111\/exd.14619.","journal-title":"Exp Dermatol"},{"key":"687_CR96","unstructured":"National Library of Medicine. A Randomised, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients. Available at: https:\/\/clinicaltrials.gov\/study\/NCT02421172. Accessed 28 May 2024."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00687-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00687-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00687-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T21:24:36Z","timestamp":1737494676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00687-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00687-w","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"24 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Orhan Yilmaz has no conflicts of interest. Gon\u00e7alo Pinto Salgueiro has no conflicts of interest. Miguel Nogueira has received consultancy and\/or speaker\u2019s honoraria from AbbVie and LEO Pharma. Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent to Participate\/Publish"}},{"value":"Data availability is not applicable to this article as no new data were created or analyzed in this study. This is a narrative review, and all sources of information are cited appropriately in the article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All the authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contribution"}}]}}